We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
TSXV:TMD | TSX Venture | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0 | - |
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES Titan Medical Inc. ("Titan" or the "Company") (TSX VENTURE:TMD)(OTCQX:TITXF) announced today that the 9,142,500 previously issued warrants, forming part of the February 19, 2014 offering of units, have been listed on the TSX Venture Exchange. The warrants, designated as March 2017 Warrants, will trade under the symbol "TMD.WT.D" and bear the CUSIP number, 88830X181. Each March 2017 Warrant entitles the holder to purchase one common share of Titan for $2.00 and expires on February 19, 2017. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of Titan. About Titan Medical Inc. Titan Medical Inc. is a Canadian public company focused on the design and development of a robotic surgical system for application in minimally invasive surgery ("MIS"). The Company's Single Port Orifice Robotic Technology, SPORT(TM) Surgical System, currently under development, comprises a surgeon-controlled robotic platform that includes a 3D vision system and interactive instruments for performing MIS procedures, and a surgeon workstation that provides the surgeon with an interface to the robotic platform for controlling the interactive instruments and providing a 3D endoscopic view of inside a patient's body during MIS procedures. The SPORT(TM) Surgical System is being designed to expand robotic surgery into areas of surgical specialties and simple and complex procedures that are currently under-serviced, and to allow surgeons to perform procedures within small to medium size surgical spaces such as general surgery and cholecystectomy. For more information, visit the Company's website at www.titanmedicalinc.com. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. FOR FURTHER INFORMATION PLEASE CONTACT: Titan Medical Inc. John Hargrove Chairman and Chief Executive Officer (416) 548-7522 (ext. 151) john.hargrove@titanmedicalinc.com www.titanmedicalinc.com Investor Relations Beverly Brooks (416) 482-8889 brooks.communications@rogers.com
1 Year Chart |
1 Month Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions